Swiss National Bank
TRVI icon

Swiss National Bank’s Trevi Therapeutics TRVI Stock Holding History

Swiss National Bank’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.59M Buy
192,300
+24,100
+14% +$350K ﹤0.01% 1632
2026
Q1 		$2.01M Hold
168,200
– – ﹤0.01% 1848
2025
Q4 		$2.11M Buy
168,200
+6,500
+4% +$75.1K ﹤0.01% 1846
2025
Q3 		$1.48M Buy
+161,700
New +$1.21M ﹤0.01% 1993

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Swiss National Bank's TRVI Position: Q2 2026 in Review

Swiss National Bank increased its Trevi Therapeutics (TRVI) stake by 14% in Q2 2026, buying an estimated $350K and bringing the position to 192,300 shares worth $3.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Swiss National Bank first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Swiss National Bank held 192,300 shares of Trevi Therapeutics worth $3.59M as of Q2 2026.
  • Swiss National Bank bought 24,100 Trevi Therapeutics shares in Q2 2026, an estimated $350K.
  • Trevi Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1632 holding.
  • Swiss National Bank first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.